The south-western Black Forest and the Upper Rhine Graben Main Border Fault: thermal history and hydrothermal fluid flow

The thermal history of the south-westernmost Black Forest (Germany) and the adjacent Upper Rhine Graben were constrained by a combination of apatite and zircon fission-track (FT) and microstructural analyses. After intrusion of Palaeozoic granitic plutons in the Black Forest, the thermal regime of the studied area re-equilibrated during the Late Permian and the Mesozoic, interrupted by enhanced hydrothermal activity during the Jurassic. At the eastern flank of the Upper Rhine Graben along the Main Border Fault the analysed samples show microstructural characteristics related to repeated tectonic and hydrothermal activities. The integration of microstructural observations of the cataclastic fault gouge with the FT data identifies the existence of repeated tectonic-related fluid flow events characterised by different thermal conditions. The older took place during the Variscan and/or Mesozoic time at temperatures lower than 280°C, whereas the younger was probably contemporary with the Cenozoic rifting of the Upper Rhine Graben at temperatures not higher than 150°

The impact of the Jurassic hydrothermal activity on zircon fission track data from the southern Upper Rhine Graben area

The influence of the Jurassic hydrothermal activity on the interpretation of fission track (FT) data from the southern Upper Rhine Graben (URG) is elaborated by means of new zircon FT analyses on samples with known U/Pb crystallisation ages. Zircon FT central ages display a wide spectrum from 162 ± 14 Ma to 247 ± 22 Ma. The combination of the U/Pb ages, independent geologic evidence (such as Mesozoic subsidence history, timing of hydrothermal activity, and apatite FT ages) and the zircon FT data unambigously indicate a Jurassic thermal overprint in the investigated area. It is suggested that circulating hydrothermal fluids with temperatures in the order of 200-250 °C were responsible for the observed thermal anomaly. The Jurassic hydrothermal fluid migration appears to have been related to a heating event on a regional scale. Inferences from FT analyses related to burial or denudation history have to take into account how such hydrothermal events affect the FT system, including a changing geothermal gradient with time

The south-western Black Forest and the Upper Rhine Graben Main Border Fault : thermal history and hydrothermal fluid flow

The thermal history of the south-westernmost Black Forest (Germany) and the adjacent Upper Rhine Graben were constrained by a combination of apatite and zircon fission-track (FT) and microstructural analyses. After intrusion of Palaeozoic granitic plutons in the Black Forest, the thermal regime of the studied area re-equilibrated during the Late Permian and the Mesozoic, interrupted by enhanced hydrothermal activity during the Jurassic. At the eastern flank of the Upper Rhine Graben along the Main Border Fault the analysed samples show microstructural characteristics related to repeated tectonic and hydrothermal activities. The integration of microstructural observations of the cataclastic fault gouge with the FT data identifies the existence of repeated tectonic-related fluid flow events characterised by different thermal conditions. The older took place during the Variscan and/or Mesozoic time at temperatures lower than 280A degrees C, whereas the younger was probably contemporary with the Cenozoic rifting of the Upper Rhine Graben at temperatures not higher than 150A degrees C

Origin of high Zn contents in Jurassic limestone of the Jura mountain range and the Burgundy: evidence from Zn speciation and distribution

ISSN:1661-8734ISSN:1661-872

The Chironico landslide (Valle Leventina, southern Swiss Alps): age and evolution

ISSN:1661-8734ISSN:1661-872

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Background: In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in the intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, and a clinically meaningful overall survival (OS) effect in PD-L1-positive aTNBC. The phase III KEYNOTE-355 trial adding pembrolizumab to chemotherapy for aTNBC showed similar PFS effects. IMpassion131 evaluated first-line atezolizumab\u2013paclitaxel in aTNBC. Patients and methods: Eligible patients [no prior systemic therapy or 6512 months since (neo)adjuvant chemotherapy] were randomised 2:1 to atezolizumab 840 mg or placebo (days 1, 15), both with paclitaxel 90 mg/m2 (days 1, 8, 15), every 28 days until disease progression or unacceptable toxicity. Stratification factors were tumour PD-L1 status, prior taxane, liver metastases and geographical region. The primary endpoint was investigator-assessed PFS, tested hierarchically first in the PD-L1-positive [immune cell expression 651%, VENTANA PD-L1 (SP142) assay] population, and then in the ITT population. OS was a secondary endpoint. Results: Of 651 randomised patients, 45% had PD-L1-positive aTNBC. At the primary PFS analysis, adding atezolizumab to paclitaxel did not improve investigator-assessed PFS in the PD-L1-positive population [hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.60-1.12; P = 0.20; median PFS 6.0 months with atezolizumab\u2013paclitaxel versus 5.7 months with placebo\u2013paclitaxel]. In the PD-L1-positive population, atezolizumab\u2013paclitaxel was associated with more favourable unconfirmed best overall response rate (63% versus 55% with placebo\u2013paclitaxel) and median duration of response (7.2 versus 5.5 months, respectively). Final OS results showed no difference between arms (HR 1.11, 95% CI 0.76-1.64; median 22.1 months with atezolizumab\u2013paclitaxel versus 28.3 months with placebo\u2013paclitaxel in the PD-L1-positive population). Results in the ITT population were consistent with the PD-L1-positive population. The safety profile was consistent with known effects of each study drug. Conclusion: Combining atezolizumab with paclitaxel did not improve PFS or OS versus paclitaxel alone. ClinicalTrials.gov: NCT03125902